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S U M M A R Y
Objective: To assess whether African ethnicity is independently associated with a poorer CD4
reconstitution with highly active antiretroviral therapy (HAART) compared to Caucasian ethnicity.
Methods: We conducted a retrospective epidemiological study among 575 HIV-1-positive patients at
our center and deﬁned immunological success as the presence of blood CD4 lymphocyte counts >500
cells/mm3 in more than 50% of the values collected from 6 to 48 months after beginning HAART. Patients
displaying an HIV-1 viral load >200 copies/ml or more than one HIV-1 viral load between 20 and 200
copies/ml during follow-up, were excluded. Patients with baseline blood CD4 counts >500 cells/mm3
were also excluded.
Results: Two hundred and eighty patients met the inclusion criteria and no exclusion criteria. After 48
months of HAART, blood CD4 lymphocyte counts were lower in Africans than in Caucasians: 449 (65–
975) vs. 569 (131–1698) cells/mm3 (p = 0.02). Immunological success was present in 142/220 (64.5%)
Caucasians vs. 29/60 (48.3%) Africans (p = 0.02). African ethnicity was independently associated with the
absence of immunological success (odds ratio 2.22, 95% conﬁdence interval 1.097–4.504; p = 0.02)
despite similar baseline blood CD4 counts (219 vs. 204 cells/mm3, p = 0.72).
Conclusion: Our ﬁndings suggest that African ethnicity is independently associated with a poorer CD4
reconstitution during HAART than Caucasian ethnicity.
 2013 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Patients of African origin still bear the heaviest burden of the
HIV pandemic.1 These patients have absolute peripheral blood CD4
lymphocyte counts similar to those of Caucasian patients2, but
signiﬁcant immunological discrepancies have been seen in
patients of African origin.3
During the natural course of HIV infection, the CD4+ count
decreases more slowly in patients of African origin than in
Caucasian patients.4 Previous studies have found the CD4+ count
increase with highly active antiretroviral therapy (HAART) not to
be signiﬁcantly different between HIV-infected patients of African§ Data from this manuscript were presented at the 23rd European Congress of
Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 27–30, 2013,
and the 14e Journe´es Nationales d’Infectiologie, Clermont-Ferrand, France,
June 12–14, 2013.
* Corresponding author. Tel.: +33 3 26 78 94 22; fax: +33 3 26 78 40 90.
E-mail address: yohan.nguyen@wanadoo.fr (Y. N’Guyen).
1201-9712/$36.00 – see front matter  2013 Published by Elsevier Ltd on behalf of In
http://dx.doi.org/10.1016/j.ijid.2013.08.001origin and HIV-infected Caucasian patients.5 Only one investiga-
tion has reported evidence of a greater CD4+ count increase in
Caucasian patients compared to patients of African origin during
the ﬁrst months of HAART.6 Discrepancies between these studies
could be linked to the low number of patients of African origin
compared to the Caucasian patients, to the various geographic
origins of patients of African origin, and to the time delay between
the diagnosis of HIV infection and the initiation of HAART, as well
as the potential impact of HIV-1 subtypes.7
The effect of ethnicity on the CD4 immune reconstitution during
HAART remains an unsolved question, the answer to which could be
of major interest. We conducted a retrospective epidemiological
investigation to assess whether African ethnicity is independently
associated with a poorer CD4 reconstitution during HAART.
2. Patients and methods
Five hundred and seventy-ﬁve HIV-1-infected adult patients
under HAART on December 31, 2011, at the Reims Universityternational Society for Infectious Diseases.
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digitization of their medical records using Nadis software, were
included.
Socio-demographic, clinical, and immuno-virological data
(HIV-1 subtype, CD4+ count, and HIV-1 viral loads at baseline
and during follow-up at 6, 9, 12, 18, 24, 36, and 48 months after
beginning HAART) were extracted from Nadis. This database has
been declared to the Commission Nationale Informatique et
Liberte´ (number 1585477).
The baseline CD4+ count was deﬁned as the lowest absolute
value before HAART. Immunological success (IS) was deﬁned as the
presence of a CD4+ count >500 cells/mm3 in more than 50% of the
values collected during follow-up.8
Age, US Centers for Disease Control and Prevention (CDC)
classiﬁcation category B or C, and HIV-1 viral load at baseline were
those extracted before the ﬁrst line of HAART in patients with
multiple lines of therapy. The last line was considered for immuno-
virological data collection during follow-up, except when a
previous line had lasted more than 48 months without any
signiﬁcant HIV-1 viral load variations (see exclusion criteria
described below).
In accordance with the ANRS (Agence Nationale de Recherche
sur le SIDA et les He´patites Virales) algorithm,9 HIV-1 subtype was
deﬁned as non-B in the presence of mutations at positions 35, 36,
61, 69, and 89 during routine pol gene sequencing.
The following patients were excluded: those displaying an
HIV-1 viral load >20 copies/ml (TaqMan, Roche) 6 months after
beginning HAART and those displaying an HIV-1 viral load >200
copies/ml, or more than one HIV-1 viral load between 20 and 200Figure 1. (A) Blood CD4 lymphocyte count evolution at baseline and at 48 months (m48) 
infected patients of African origin (African). *Median CD4 lymphocyte count absolute va
Caucasian and African patients, respectively (p = 0.02). **Median CD4 lymphocyte count a
in Caucasian and African patients, respectively (p = 0.63). Upper-right corner: mean CD4
Caucasian and African patients. (B) Variables signiﬁcantly associated with the absence of 
CD4 cell count absolute values >500 cells/mm3 in more than 50% of the values collected
missing data; OR, odds ratio; 95% CI, 95% conﬁdence interval. *p-Value univariate ana
goodness-of-ﬁt gives p = 0.163. ‘HIV-1 subtype non-B’ and ‘opportunistic infection’ were
‘CDC classiﬁcation category B or C’, respectively (Table 1).copies/ml, from 9 to 48 months after beginning HAART. Patients
lost to follow-up, with a duration of follow-up less than 9 months,
and patients with a baseline CD4+ count >500 cells/mm3were also
excluded.
2.1. Statistical analysis
Quantitative variables were compared using the Mann–
Whitney U-test and qualitative variables were compared using
Fisher’s exact test or Pearson’s Chi-square test, as appropriate. A p-
value of <0.05 was considered signiﬁcant. All variables with a p-
value of <0.20 were entered into a multiple logistic regression
model. Statistical analyses were performed using StatView 5.0
software (SAS Institute, Cary, NC, USA).
3. Results
Two hundred and twenty (78.6%) Caucasian patients and 60
(21.4%) patients of African origin met the inclusion criteria and none
of the exclusion criteria (Table 1). Study patients of African origin
came mainly from West Africa (92%). Excluded patients were
Caucasian in 80.7% of cases and patients of African origin in 19.3% of
cases. HIV-1 viral loads decreased after initiation of ﬁrst-line HAART
in both groups (see Supplementary Material, Figure S1).
At 36 and 48 months after initiation of HAART, CD4+ counts were
different between patients of African origin (n = 38 and 31) and
Caucasian patients (n = 167 and 148): 469 (93–677) vs. 528 (45–
1383) at 36 months (p = 0.03), and 449 (65–975) vs. 569 (131–1698)
cells/mm3 at 48 months (p = 0.02). CD4+ count reconstitutionafter beginning HAART in HIV-1-infected Caucasian patients (Caucasian) and HIV-1-
lues at 48 months were 574 (range 131–1698) vs. 449 (range 65–975) cells/mm3 in
bsolute values at baseline were 188 (range 1–479) and 195 (range 4–396) cells/mm3
 lymphocyte count evolution at baseline and 48 months after beginning HAART in
immunological success. Immunological success was deﬁned as the presence of blood
 during follow-up at 6, 9, 12, 18, 24, 36, and 48 months after beginning HAART. MD,
lysis. **p-Value multivariate analysis. aFisher’s exact test. Hosmer and Lemeshow
 not included in the model because of collinearity with variables ‘African origin’ and
Table 1
Characteristics of Caucasian patients and patients of African origin included in the study.
Characteristics African origin
n = 60 (100%)
Caucasian
n = 220 (100%)
Missing data p-Value
Mean age, years 40.1 50.3 0 <0.0001
Age >50 years at the beginning of HAART, n (%) 3 (5.0%) 61 (27.7%) 0 <0.0002
Male sex, n (%) 15 (25.0%) 174 (79.1%) 0 <0.0001
Sexual transmission, n (%) 54 (90.0%) 192 (87.2%) 15 0.14a
Chronic B or C viral hepatitis, n (%) 10 (16.6%) 32 (14.5%) 0 0.68
Median number of years since diagnosis of HIV-1 seropositivity (min–max) 7 (2–20) 14 (2–28) 0 <0.0001
CDC classiﬁcation category B or C at the beginning of HAART, n (%) 18 (30.0%) 103 (46.9%) 0 0.02
Opportunistic infection, n (%) 17 (28.3%) 101 (45.9%) 0 0.01
Tuberculosis, n (%) 4 (6.6%) 3 (1.3%) 0 0.04a
Median baseline blood CD4 cell count absolute value, cells/mm3 (min–max) 219 (3–415) 204 (1–479) 9 0.72
Patients with HIV-1 viral load >5 log10 (copies/ml) at baseline, n (%) 18 (30.0%) 70 (31.8%) 19 0.96
Median baseline HIV-1 viral load, copies/ml (min–max) 47 414 (20–3 191 780) 44 781 (39–10 000 000) 19 0.77
HAART regimen including protease inhibitor, n (%) 45 (75.0%) 183 (83.1%) 0 0.14
HIV-1 subtype non-B, n (%) 32 (53.3%) 6 (2.7%) 89 <0.0001
HAART, highly active antiretroviral therapy; CDC, US Centers for Disease Control and Prevention.
a Fisher’s exact test.
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counts available at baseline and at 48 months. The CD4 increase
slope appeared to be steeper in Caucasian patients than in patients of
African origin, but this was without statistical signiﬁcance (p = 0.09).
Eighty-seven of the 150 Caucasian patients and only 10 of the 27
patients of African origin had a CD4+ count >500/mm3 at 48 months
(p = 0.04).
Immunological success was present in 142 of the 220 Caucasian
patients (64.5%) vs. 29 of the 60 patients of African origin (48.3%)
(p = 0.02). Variables signiﬁcantly associated with the absence of
immunological success are depicted in Figure 1B. African ethnicity
was independently associated with the absence of immunological
success (odds ratio 2.22, 95% conﬁdence interval 1.097–4.504;
p = 0.02). African origin continued to be independently associated
with the absence of immunological success after adjustment for
age and even when immunological success was deﬁned as the
presence of a CD4+ count >500 cells/mm3 twice during follow-up
(data not shown). Among the 177 patients with CD4+ counts
available at baseline and up to 48 months after beginning HAART,
immunological success was present in 10 out of the 27 patients of
African origin (37.0%) vs. 102 out of the 150 Caucasian patients
(68.0%) (p = 0.002).
4. Discussion
In the present study, CD4+ counts were found to be signiﬁcantly
lower in patients of African origin than in Caucasian patients at 36
and 48 months after the initiation of HAART. Rates of patients with
CD4+ counts >500 cells/mm3 at 48 months were also signiﬁcantly
lower in patients of African origin than in Caucasian patients,
whereas baseline CD4+ counts were not signiﬁcantly different
between the two patients groups. Both the use of drastic exclusion
criteria designed to rule out lack of adherence to HAART and our
patients of African origin group mainly originating from West
Africa and accounting for 20% of study patients, allowed us to
properly assess the dynamics of CD4+ count recovery according to
ethnicity. However our results could be linked to the small number
of patients of African origin at 48 months and to an insufﬁcient
duration of follow-up. In our study, follow-up was stopped at 48
months because this time was considered as the time of steady-
state for CD4+ count recovery.10
Because we observed that patients of African origin have a
lesser propensity to reach CD4+ counts >500 cells/mm3 and
because that threshold value is known to be correlated with a
life-expectancy similar to that of the general population,8 we
assessed whether our immunological success criteria wereindependently associated with African ethnicity. Using our
criteria, African ethnicity was the only factor independently
associated with the absence of immunological success, except
the baseline CD4+ count, which has been described previous-
ly.5,10 The effect of HIV-1 subtype non-B could not be excluded
because of collinearity. In any case, taking all these results
together, we could ask ourselves whether patients of African
origin should not be treated earlier in order to deﬁnitely obtain a
CD4+ count >500 cells/mm3.8 Such early treatment could be
justiﬁed only if we have ﬁrst demonstrated that survival of
patients of African origin is the same as in the general
population, after adjustment for confounding factors such as
HIV-1 subtype non-B, which has been associated once with a
better immunological outcome in a different study setting.7
Compared to this previous study, which was designed to focus
on the modelization of the CD4+ increase slope of non-B HIV-1
HAART-treated patients at the primary infection stage, our
retrospective investigation was designed to focus on the
propensity of HAART-treated African patients to restore their
CD4+ count >500 cells/mm3 during the 48 months following the
beginning of HAART. Such design discrepancies could explain
the differences in results obtained in the previous study and
ours.
In conclusion, our ﬁndings suggest that African ethnicity is
independently associated with a poorer CD4 reconstitution during
HAART than Caucasian ethnicity. Further prospective studies with
larger numbers of patients of African origin and a follow-up longer
than 48 months would be of major interest.
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